Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

RA-ILD: target trial emulation of Abatacept and Rituximab

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis & Rheumatology

Citation & Authors

Arthritis Rheumatol. 2026;78(3):592–602.

Po-Cheng Shih; Shiow-Ing Wang; James Cheng Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The TriNetX target trial emulation compared treatments for RA-ILD, with 1,615 patients per group after matching. Abatacept was associated with lower risks of death (HR 0.689; 95% CI 0.581–0.818) and mechanical ventilation (0.698; 0.521–0.934), with consistent directions in sensitivity analyses. However, clinicians may preferentially prescribe abatacept to patients with milder disease. Confounding by indication cannot be excluded, and a causal survival advantage cannot be established.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

After matching, each group included 1,615 patients. Abatacept was associated with a lower risk of all-cause mortality (HR 0.689; 95% CI 0.581–0.818).

Residual confounding related to treatment indication and disease severity may remain; causality cannot be established from these findings.